Cingulate Announces Q3 Net Loss of $7.3 Million Compared to $4.1 Million Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Financial Status: As of September 30, 2025, Cingulate reported approximately $6.1 million in cash and cash equivalents, reflecting a decrease from December 31, 2024.
Capital Needs: The company anticipates needing to raise about $7.0 million in additional capital to support commercialization efforts leading up to the May 31, 2026 PDUFA date for CTx-1301.
Working Capital: Cingulate's working capital stood at approximately $1.6 million as of September 30, 2025, down from $7.7 million at the end of 2024.
Future Projections: The company expects its current cash reserves will meet its capital needs into the second quarter of 2026 under the existing business plan.
Analyst Views on CING
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 27.33 USD with a low forecast of 8.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.040
Low
8.00
Averages
27.33
High
58.00
Current: 5.040
Low
8.00
Averages
27.33
High
58.00
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
